MiFID Not an Advantage for U.S. Research, Says Bevan

The video discusses the confusion surrounding research benefits, focusing on the US and EU jurisdictions. It highlights the roles of different players, such as fund managers and broker dealers, and the challenges of unbundling research. The video also addresses the regulatory issues and the impact on competitive advantage. As the deadline approaches, there is chaos in pricing strategies, with a clear trend towards the buy side paying in cash, benefiting customers. However, ambiguity remains in pricing strategies for the sell side.

What is the trend regarding the buy side's approach to pricing, according to the text?

What ambiguity remains about pricing strategies in the sell side broking community?